Hemodynamic Effects of BPA at Rest and During Exercise in CTEPH
Launched by AARHUS UNIVERSITY HOSPITAL · Aug 8, 2019
Trial Information
Current as of June 24, 2025
Unknown status
Keywords
ClinConnect Summary
Chronic thromboembolic pulmonary hypertension \[CTEPH\] is a rare condition with a significant risk of morbidity and mortality. The primary cause of CTEPH is thrombotic lesions, which did not resolve after acute pulmonary embolism. This causes increased pulmonary vascular resistance \[PVR\], leading to secondary remodeling of pulmonary arteries causing pulmonary hypertension and ultimately progressive right heart failure. The treatment of choice is surgical pulmonary endarterectomy \[PEA\], however up to 40% cases are not treated surgically, due to operability, anatomic location of the lesi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Patients with CTEPH or CTED eligible for balloon pulmonary angioplasty.
- Exclusion Criteria:
- • -Patients unable to perform ergometer exercise
About Aarhus University Hospital
Aarhus University Hospital is a leading research institution in Denmark, dedicated to advancing medical science and improving patient care through innovative clinical trials. As a key sponsor of clinical research, the hospital integrates cutting-edge technology and multidisciplinary expertise to conduct studies that address critical health challenges. With a commitment to ethical standards and patient safety, Aarhus University Hospital collaborates with a diverse network of academic and industry partners, ensuring that its research initiatives contribute to the global body of medical knowledge and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aarhus, , Denmark
Nagoya, , Japan
Otwock, , Poland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials